The health and safety of our patients, families and staff is our highest priority. Due to the COVID-19 pandemic, the Commonwealth of Massachusetts is requiring hospitals to meet established criteria as part of the state’s reopening plan. The Boston Shriners Hospital completed its Phase 1 attestation on May 27, 2020, and its Phase 2 attestation on June 15, 2020 and its Phase 3 attestation on July 13, 2020. The Phase 3 attestation was resubmitted and reaffirmed on November 16, 2020. The Boston Shriners Hospital also completed and submitted the state’s resurgence attestation on November 16, 2020.

If your child has an upcoming appointment, please contact your local Shriners Hospitals for Children location.

Shriners Hospitals for Children — Boston visitor information.

Skip to navigation

H. Shaw Warren, M.D.

H. Shaw Warren, M.D.

H. Shaw Warren, M.D., is on the medical and scientific staff at Shriners Hospitals for Children — Boston. Dr. Warren is also a physician and pediatrician at Massachusetts General Hospital and an associate professor of pediatrics at Harvard Medical School.

Dr. Warren is trained in internal medicine and infectious diseases and has 25 years of experience studying inflammation and sepsis in burned children in the laboratory and clinic. He has extensive experience in the design, analysis and review of clinical trials for severe inflammation and sepsis and sees patients on the infectious disease service at Massachusetts General Hospital and Shriners Hospitals for Children — Boston. Specific interests include the development of drugs for severe inflammation and sepsis, the use of animal models for understanding pathophysiology of inflammation and sepsis, and the response of different species to microbial challenge, especially in burn injury and wound healing.

Dr. Warren has been part of the Shriners Hospitals for Children research team for 30 years. His laboratory has studied infections in burn wounds and the secondary inflammation that has been induced with particular interest in the ways that Gram-negative bacteria and the released bacterial cell membranes interact with host immune cells, and treating Gram-negative infections. As part of federal and Shriners Hospitals for Children funded projects, Dr. Warren’s laboratory has been studying hemopexin, a plasma protein with high affinity for heme, which suppresses activation of macrophages. This work, together with clinical findings that mortality in critical illness is associated with increased plasma heme and hemoglobin and decreased hemopexin, has led the team and others to propose that hemopexin could have therapeutic value as a treatment strategy in patients who have heme driven inflammation, such as in patients with burn injury. Dr. Warren’s research team is now seeking ways to develop hemopexin (and the related molecule haptoglobin) for clinical use in critical care settings such as after severe burn injury.

Dr. Warren has 89 published articles, 12 reviews, chapters, monographs and editorials, nine chapters in books/textbooks for the medical or scientific community, six case reports or letters to the editor and numerous ad hoc NIH and non-NIH study section reviews.

Dr. Warren has had scientific funding from U.S. governmental agencies for over 30 years. He is a former Fulbright scholar and has received numerous individual grant or scholarship awards, including the Milton-Harvard award, the Mosely award from Harvard Medical School, the Hood award during early training, and the Partners Healthcare Innovation Development Award in 2014.

Current positions:

  • Medical and Scientific Staff, Shriners Hospitals for Children — Boston
  • Physician, Pediatrician, Massachusetts General Hospital (MGH)
  • Associate Professor of Pediatrics, Harvard Medical School


  • BA, Biology, Harvard College, Cambridge, Mass.
  • M.D., Harvard Medical School, Cambridge, Mass.
  • Intern in Medicine, North Carolina Memorial Hospital, Chapel Hill, N.C.
  • Resident in Medicine, Beth Israel Hospital, Boston, Mass.
  • Fellowship, Infectious Diseases, Beth Israel and Brigham and Women's Hospitals, Boston, Mass.
  • Research Fellow, Infectious Diseases, Dana Farber Cancer Institute
  • Senior Research Fellow, Dept. of Experimental Immunotherapy, Institut Pasteur, Paris, France

Scholarly activities: